Cargando…
AB130. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway
Males have a higher incidence of renal cell carcinoma (RCC) than females, but the reason for this gender difference is unknown. Addressing this question, we report the discovery of an androgen receptor (AR)-induced HIF2α/VEGF signal that drives RCC progression. AR attenuation or augmentation in RCC...
Autores principales: | He, Dalin, Li, Lei, Zhu, Gguodong, Liang, Liang, Guan, Zhenfeng, Chang, Luke, Chen, Yuan, Yeh, Shuyuan, Chang, Chawnshang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708530/ http://dx.doi.org/10.3978/j.issn.2223-4683.2014.s130 |
Ejemplares similares
-
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
por: Huang, Chi-Ping, et al.
Publicado: (2019) -
Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression
por: Izumi, Kouji, et al.
Publicado: (2013) -
New therapy with ASC-J9(®) to suppress the prostatitis via altering the cytokine CCL2 signals
por: Lin, Shin-Jen, et al.
Publicado: (2016) -
ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
por: Tian, Hao, et al.
Publicado: (2021) -
Androgen Receptor Enhances Kidney Stone-CaOx Crystal Formation via Modulation of Oxalate Biosynthesis & Oxidative Stress
por: Liang, Liang, et al.
Publicado: (2014)